Alamar Biosciences (ALMR) Director Robert P. Ragusa Receives RSU Award

What Happened

• Director Robert P. Ragusa received equity awards from Alamar Biosciences on September 1, 2026: 5,686 shares reported as an acquired award and 25,599 shares reported as a derivative award. Both awards were reported with a grant price/value of $0 in the Form 4.

Key Details

• Transaction date: September 1, 2026; Form 4 filed September 3, 2026 (within the typical two-business-day reporting window).
• Awards and reported values: 5,686 shares @ $0 (award); 25,599 derivative shares @ $0 (derivative award).
• Vesting/terms (per filing footnotes):
  • RSU award (footnote F1): the RSUs vest in equal annual installments over 3 years measured from September 1, 2026, subject to the reporting person’s continuous service at each vesting date.
  • Derivative/option-style award (footnote F2): one-third of the shares will vest on September 1, 2027; the remainder vests in equal monthly installments thereafter through September 1, 2029, subject to continuous service.
• Shares owned after the transaction: not specified in the provided filing details.
• No indication of a sale, cashless exercise, tax withholding disposition, or a 10b5-1 plan in the submitted information.

Context

• These were grant/award transactions (not open-market purchases or sales). Awards reported at $0 typically reflect non-cash compensation grants (e.g., RSUs or option awards) rather than a market transaction. Vesting is service-based, so the shares (or option rights) will become transferable or exercisable over time if the director remains in service.